Riociguat (Adempas®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001097
English
Authors' recommendations:
Riociguat (Adempas®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO functional class II to III to improve exercise capacity. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Riociguat (Adempas®) should be restricted for use as a PAH-specific monotherapy as an alternative treatment option to endothelin receptor antagonist (ERA) monotherapy in adult patients with PAH of WHO functional class II to III. Riociguat (Adempas®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/558
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Soluble Guanylyl Cyclase
- Pulmonary Arterial Hypertension
- Enzyme Activators
- Adult
- Hypertension, Pulmonary
- Pyrazoles
- Pyrimidines
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.